HRA Pharma

ellaOne® emergency contraceptive launched in Italy by HRA Pharma


  Read more…

Ulipristal Acetate Granted European Marketing Authorisation for the treatment of symptoms of Uterine Fibroids


  Read more…

NEJM features two positive pivotal trials of HRA Pharma compound ulipristal acetate for the treatment of uterine fibroids


  Read more…

HRA Pharma’s partner, Preglem, the wholly owned subsidiary of Gedeon Richter Plc., receives positive CHMP opinion for uterine fibroids treatment.


  Read more…

HRA Pharma grants Richter marketing rights for Esmya for China, Russia and other CIS republics


  Read more…

Riverside provides growth capital to France‘s HRA Pharma


  Read more…

HRA Pharma wins the 2011 Prix de l^’Ambition
The award recognizes outstanding international development of the company.

  Read more…

ella^® approved in Singapore
Singapore becomes the first country in South-East Asia to approve ella^®, the new generation of emergency contraception

  Read more…

First Launch of ellaOne^® in Asia
South Korea becomes the first Asian country to have access to the new generation of emergency contraception.

  Read more…

HRA Pharma welcomes the launch of NorLevo^® as the first Emergency Contraceptive Pill to become available in Japan
HRA Pharma has welcomed today’s launch of its oral emergency contraceptive NorLevo® (levonorgestrel 0.75mg tablets) in Japan by the biopharmaceutical company Sosei Co. Ltd, part of the Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565). It is the first emergency contraceptive to be launched in the country.

  Read more…

ASKA Pharmaceutical and HRA Pharma Announce Exclusive Licensing Agreement for ulipristal acetate to treat uterine fibroids in Japan
ASKA Pharmaceutical Co., LTD and HRA Pharma have announced the conclusion of exclusive licensing agreements for ASKA Pharmaceutical to develop and market ulipristal acetate in Japan.

  Read more…

ASKA Pharmaceutical and HRA Pharma Announce Exclusive Licensing Agreement for ellaOne® in Japan
ASKA Pharmaceutical Co., LTD and HRA Pharma have announced the conclusion of exclusive licensing agreements for ASKA Pharmaceutical to develop and market ulipristal acetate in Japan in response to multiple women’s reproductive health issues, in particular emergency contraception.

  Read more…

NorLevo^® the First Emergency Contraceptive to Receive Marketing Approval in Japan.

  Read more…

HRA Pharma's NorLevo^® Now the First Emergency Contraceptive Available Without a Prescription in Ireland.

  Read more…

HRA Pharma Enters into Agreement with Chemo to Commercialize Novel Emergency Contraceptive in Central and South America.

  Read more…

Shin Poong Pharma and HRA Pharma Announce Exclusive Licensing Agreement for Ulipristal Acetate in South Korea.

  Read more…

HRA Pharma’s Emergency Contraceptive ella^® Now Available in the U.S.
U.S. launch marks major milestone for European company focused on developing innovative technologies for reproductive health and endocrinology.

  Read more…

ellaOne® now reimbursed in France.

  Read more…

HRA Pharma and Watson Pharmaceuticals Expand Marketing Partnership for Novel Emergency Contraceptive to Canada.
Agreement follows FDA approval of ella® in the U.S., where Watson will market the product.

  Read more…

Erin Gainer, CEO of HRA Pharma, Recognized for Her Leadership Role in the Pharmaceutical Industry.

  Read more…

FDA grants approval of ella® for emergency contraception.
Novel emergency contraceptive developed by HRA Pharma to be marketed by Watson Pharmaceuticals in the US before the end of 2010.

  Read more…

Ulipristal acetate (ellaOne®) significantly reduces pregnancy risk versus levonorgestrel for oral emergency contraception.
European Medicines Agency confirms findings from HRA Pharma's most recent data

  Read more…

FDA Advisory Committee Unanimously Recommends Approval of HRA Pharma's Ulipristal Acetate for Emergency Contraception.

  Read more…

HRA Pharma's Partner Preglem Announces Positive Phase III Results for Ulipristal Acetate in the Treatment of Uterine Fibroids.
Ulipristal acetate a step closer to becoming a breakthrough medical treatment for uterine fibroids.

  Read more…

HRA Pharma Announces FDA Advisory Committee Review of Ulipristal Acetate.

  Read more…

Preglem licenses additional rights for ulipristal acetate from HRA Pharma.
To develop a first-in-class myoma (fibroid) treatment for North American market.

  Read more…

HRA Pharma's new-generation emergency contraceptive ellaOne^® accepted by the Scottish Medicines Consortium.
The Scottish Medicines Consortium has become the latest UK drug assessment watchdog to accept the use of this new emergency contraceptive.

  Read more…

Watson and HRA Pharma Announce Exclusive Licensing Agreement to Commercialize Novel Emergency Contraceptive in the U.S.
New data published in The Lancet demonstrate effective pregnancy prevention as compared to currently available emergency contraceptive options.

  Read more…

Breaking News in Emergency Contraception: HRA Pharma Unveils Clinical Data on ellaOne^®.
Groundbreaking clinical trials on new generation emergency contraceptive published simultaneously in The Lancet and Obstetrics & Gynecology.

  Read more…

HRA Pharma Expands to Spain and Launches ellaOne^®.
Independent niche pharmaceutical company tackles its fifth European market;local commercial operations to support its new generation emergency contraceptive

  Read more…

HRA Pharma's NorLevo^® on its way to becoming the first emergency contraceptive pill available in Japan.
HRA Pharma's partner Sosei signed distribution agreement with ASKA for commercialisation of NorLevo^® in Japan.

  Read more…

HRA Pharma's emergency contraceptive ella^® in motion in Asia
HRA Pharma and Orient Europharma enter into a distribution agreement to commercialize ella^®, a new generation emergency contraceptive, in Taiwan, Hong Kong and Macao.

  Read more…

HRA Pharma Marks First Step for ella^® in Asia.
HRA Pharma and Hyphens enter into a license and supply agreement to commercialize ella^®, a new generation emergency contraceptive, in Singapore and Malaysia.

  Read more…

HRA Pharma Launches ellaOne^® in Europe.
New generation emergency contraception now commercially available in France, Germany and the United Kingdom, in anticipation of upcoming launch throughout European Union.

  Read more…

HRA Pharma Announces European Marketing and Distribution Agreement with Acrux.
European specialist in reproductive health and endocrinology adds novel transdermal estradiol spray to growing product portfolio.

  Read more…

HRA Pharma Named Finalist for the 2009 Scrip Awards and the 2009 Clinical Research Excellence Awards.

  Read more…

HRA Pharma Reinforces Operational Presence in Europe with Italian Subsidiary.
Independent company with international mindset and niche therapeutic solutions now has offices in four European countries.

  Read more…

NorLevo®, HRA Pharma's Emergency Contraceptive Pill, Now Available in Canada.
European specialist in reproductive health and endocrinology teams with Bayer Inc. for launch of pioneering product.

  Read more…

HRA Pharma Marks Next Step in European Expansion with UK Subsidiary.

  Read more…

HRA Pharma Granted European Marketing Authorization for ellaOne®.
Next generation emergency contraceptive will first be launched in UK, Germany and France as company expands international operations.

  Read more…

HRA PHARMA AND PREGLEM ANNOUNCE SUCCESSFUL COMPLETION OF PHASE IIB FOR ULIPRISTAL ACETATE FOR THE TREATMENT OF UTERINE FIBROIDS.

  Read more…

HRA Pharma Appoints Erin Gainer as CEO to Lead Company Through Next Phases of International Growth.
Founder André Ulmann becomes Chairman.

  Read more…

HRA Pharma and Nycomed Reinforce Partnership with Marketing and Distribution Agreement for ellaOne®
Combination of strengths will benefit women in Nordic and Baltic countries; HRA Pharma gearing up for EU marketing authorization of revolutionary product in reproductive health.

  Read more…

HRA Pharma Receives CHMP Positive Opinion for ellaOne®
Leader in reproductive health now one step closer to providing greater contraceptive solutions to women in the European Union.

  Read more…

HRA Pharma and Gedeon Richter Enter into Marketing and Distribution Agreement
Specialists in emergency contraception team together for women's health in CEE and CIS countries

  Read more…

HRA Pharma Strengthens European Operations with German Affiliate.
Specialist in reproductive health and endocrinology marks first step in reinforcing operational presence on the continent; new entity to spearhead growth in one of Europe's largest healthcare markets

  Read more…

HRA Pharma enters licensing agreement with PregLem to develop and commercialise ulipristal for gynecological disorders.
HRA Pharma announced today that it has entered into a licensing agreement with PregLem, a Swiss specialty biopharmaceutical company, for the European development and commercialisation of HRA Pharma's selective progesterone receptor modulator, ulipristal, for the treatment of various benign gynecological disorders

  Read more…

Being aware that humanitarian programs should not be restricted to the company's area of business, and because cultural development is a necessity for development, HRA has sponsored an award at the "Rencontres africaines de la photographie" aimed to reward the work of a young African photographer who displays unique talent and a potential for excellence.

  Read more…

HRA Pharma is sponsoring the "Afrique en créations" prize aimed to reward the work of a young, talented African photographer.

  Read more

HRA Pharma commences UK-based Phase III trial of Ella^®, a second-generation emergency contraceptive
HRA Pharma today announced recruitment has begun into a UK-based pivotal Phase III study to evaluate the Company's second-generation emergency contraceptive, Ella^®. The study will be conducted across nine NHS family planning clinics in the UK.

  Read more…

HRA Pharma invest an additional € 2.5 M in cell therapy through its subsidiary Celogos
HRA Pharma, a private pharmaceutical company focused on innovative treatments in women's health and endocrinology, announced today that it has invested a further €2.5 M in its subsidiary Celogos. The funds will allow the French biotech company, a pioneer in the development of cell-based therapies for muscle disorders, to ramp up the on-going clinical development of its pipeline.

  Read more…

Stem Cell Sciences and Celogos sign a licensing deal on autogenous myoblast transplantation
Celogos, the biotechnology company focused on the development and production of innovative cell-based technologies in the field of cellular medicine, and Stem Cell Sciences KK (SCSKK), the bio-venture company specialized in regenerative medicines, have reached an agreement on the licensing of technologies for myoblast cell implantation for the treatment of stress urinary incontinence.

  Read more…

HRA Pharma commences US Phase III trial of second-generation emergency contraceptive
HRA Pharma today announced the start of a pivotal multi-centre Phase III study evaluating its proprietary second-generation emergency contraceptive – Ella^®. The study will be conducted in sixteen clinics affiliated with Planned Parenthood Federation of America (PPFA) in seven different US states.

  Read more…